Spectrum's Prior Approval Supplement for Indium-111 ZEVALIN accepted for review by FDA

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Prior Approval Supplement containing data providing for the removal of the Indium-111 ZEVALIN^® (ibritumomab tiuxetan) pre-treatment imaging evaluation, more commonly referred to as the "bioscan" requirement. A decision is expected by November 20, 2011.

SOURCE Spectrum Pharmaceuticals, Inc.